Oncolytics Biotech (ONCY) Return on Capital Employed (2010 - 2025)

Oncolytics Biotech (ONCY) has 16 years of Return on Capital Employed data on file, last reported at 394.52% in Q3 2025.

• On a quarterly basis, Return on Capital Employed fell 34393.0% year-over-year to 394.52% in Q3 2025; TTM through Sep 2025 was 394.52%, a 34393.0% decrease from a year earlier, with the FY2025 full-year figure at 652.77%, down 49516.0% from the prior year.
• Return on Capital Employed for Q3 2025 stood at 394.52%, down from 242.56% in the prior quarter.
• Over the last five years, Return on Capital Employed for ONCY reached as high as 76.93% in Q3 2021 and fell as low as 394.52% in Q3 2025.
• Historically, Return on Capital Employed has averaged 105.43% across 5 years, with a median of 105.97% in 2022.
• Across the five-year window, Return on Capital Employed jumped 15904 bps in 2024 and slumped 34393 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 83.63% in 2021, then plunged by 61 bps to 134.55% in 2022, then soared by 85 bps to 20.56% in 2023, then plunged by 787 bps to 182.38% in 2024, then slumped by 116 bps to 394.52% in 2025.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 394.52% in Q3 2025, 242.56% in Q2 2025, and 182.38% in Q4 2024.